TY - JOUR
T1 - Multimorbidity Is Associated With Symptom Severity and Disease Progression in Patients with Paroxysmal Atrial Fibrillation-Data From the RACE V Study
AU - van Deutekom, Colinda
AU - van de Lande, Martijn E.
AU - Rama, Rajiv
AU - Nguyen, Bao-Oanh
AU - Tieleman, Robert G.
AU - Weberndoerfer, Vanessa
AU - Hemels, Martin E. W.
AU - de Melis, Mirko
AU - Schotten, Ulrich
AU - Linz, Dominik
AU - Crijns, Harry J. G. M.
AU - van Gelder, Isabelle C.
AU - Rienstra, Michiel
PY - 2025/3/4
Y1 - 2025/3/4
N2 - Background: Multimorbidity is common among patients with atrial fibrillation (AF) and is associated with worse outcomes. We aimed to investigate the association between multimorbidity, AF progression and AF symptom severity in patients with paroxysmal AF. Methods and Results: The RACE V (Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodeling, and Vascular Destabilization in the Progression of AF) study included patients with paroxysmal AF and continuous rhythm monitoring. Multimorbidity was defined as >= 2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity). AF symptom severity was assessed via the University of Toronto AF Severity Scale questionnaire. The associations between multimorbidity, AF progression, and AF symptom severity were determined using logistic regression analyses. Median age was 65 (58-71) years and 179 of 417 patients (43%) were women, with a median of 1 (1-2) comorbidities. Median follow-up was 2.2 (1.6-2.8) years. Multimorbidity was associated with AF progression (odds ratio [OR], 2.02 [95% CI, 1.10-3.72], P=0.024) and increased AF symptom severity (OR, 2.67 [95% CI, 1.79-3.99], P<0.001). There was a positive dose-response relation between the number of comorbidities and AF progression (OR, 1.40 [95% CI, 1.09-1.79], P=0.008), as well as AF symptom severity (OR, 1.64 [95% CI, 1.35-1.99], P<0.001). These results remained significant after adjusting for age. Conclusions: In patients with paroxysmal AF, multimorbidity was associated with AF progression and AF symptom severity. The risk of AF progression and AF symptom severity increased with every additional comorbidity. Registration: URL: clinicaltrials.gov. Unique Identifier: NCT02726698.
AB - Background: Multimorbidity is common among patients with atrial fibrillation (AF) and is associated with worse outcomes. We aimed to investigate the association between multimorbidity, AF progression and AF symptom severity in patients with paroxysmal AF. Methods and Results: The RACE V (Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodeling, and Vascular Destabilization in the Progression of AF) study included patients with paroxysmal AF and continuous rhythm monitoring. Multimorbidity was defined as >= 2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity). AF symptom severity was assessed via the University of Toronto AF Severity Scale questionnaire. The associations between multimorbidity, AF progression, and AF symptom severity were determined using logistic regression analyses. Median age was 65 (58-71) years and 179 of 417 patients (43%) were women, with a median of 1 (1-2) comorbidities. Median follow-up was 2.2 (1.6-2.8) years. Multimorbidity was associated with AF progression (odds ratio [OR], 2.02 [95% CI, 1.10-3.72], P=0.024) and increased AF symptom severity (OR, 2.67 [95% CI, 1.79-3.99], P<0.001). There was a positive dose-response relation between the number of comorbidities and AF progression (OR, 1.40 [95% CI, 1.09-1.79], P=0.008), as well as AF symptom severity (OR, 1.64 [95% CI, 1.35-1.99], P<0.001). These results remained significant after adjusting for age. Conclusions: In patients with paroxysmal AF, multimorbidity was associated with AF progression and AF symptom severity. The risk of AF progression and AF symptom severity increased with every additional comorbidity. Registration: URL: clinicaltrials.gov. Unique Identifier: NCT02726698.
KW - atrial fibrillation
KW - comorbidities
KW - multimorbidity
KW - progression
KW - symptom severity
KW - FOLLOW-UP
KW - MECHANISMS
KW - REGISTRY
U2 - 10.1161/JAHA.123.034514
DO - 10.1161/JAHA.123.034514
M3 - Article
SN - 2047-9980
VL - 14
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 5
M1 - e034514
ER -